Literature DB >> 12412781

Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective.

D Sudhaker Rao1, Gaurav Agarwal, Gary B Talpos, Evelyn R Phillips, Franciso Bandeira, Saroj K Mishra, Ambrish Mithal.   

Abstract

Since the classic description by Fuller Albright in the 1940s, primary hyperparathyroidism has evolved from a disease with classic signs and symptoms to a disease in search of symptoms! Since that time, two major events have occurred. First, in the United States, United Kingdom, and in most European countries, there has been a steady rise in the apparent incidence of the disease. Second, there has been a dramatic shift in the pattern of presentation. A majority of patients with primary hyperparathyroidism in countries with multichannel screening panels are asymptomatic. Skeletal and renal complications are uncommon, and osteitis fibrosa is rare. In contrast, the clinical presentation of primary hyperparathyroidism has changed very little in other regions such as the East, the Middle East, and some parts of the southern hemisphere over the same period of observation. Accordingly, we assessed the influence of vitamin D and calcium nutrition on the disease expression and parathyroid tumor growth in patients with primary hyperparathyroidism from different parts of the world. Between 1945 and 1950, both the prevalence of osteitis fibrosa and parathyroid tumor weight declined dramatically in the United States, coinciding with fortification of milk with vitamin D. In contrast, osteitis fibrosa and parathyroid tumor weight changed very little in parts of the world where vitamin D depletion is endemic. Furthermore, for a comparable degree of vitamin D depletion, Asian Indians have significantly larger tumors compared with Americans (3.95 +/- 2.23 vs. 0.66 +/- 2.84 g; p < 0.001). Within the United States, blacks have larger tumors compared with whites (0.78 +/- 2.87 vs. 0.58 +/- 2.78 g; p < 0.01). However, the slopes of regression between serum 25-hydroxyvitamin D, the best index of vitamin D nutrition, and parathyroid tumor weight, the best available index of parathyroid growth, were not significantly different between Asian Indians, whites, and blacks. We conclude that vitamin D and calcium nutrition of the population affect both the clinical expression and parathyroid tumor growth in patients with primary hyperparathyroidism. It will be of interest to see if the pattern of presentation of primary hyperparathyroidism changes when better nutritional policies are implemented in developing countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412781

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  30 in total

1.  A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism.

Authors:  P Boudou; F Ibrahim; C Cormier; E Sarfati; J C Souberbielle
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

2.  The impact of vitamin D status and tumor size on the intraoperative parathyroid hormone dynamics in patients with symptomatic primary hyperparathyroidism.

Authors:  Gaurav Agarwal; Dhalapathy Sadacharan; Pooja Ramakant; Manoj Shukla; Saroj K Mishra
Journal:  Surg Today       Date:  2012-01-05       Impact factor: 2.549

3.  Vitamin D and primary hyperparathyroidism: more insights into a complex relationship.

Authors:  Marcella D Walker; John P Bilezikian
Journal:  Endocrine       Date:  2016-11-17       Impact factor: 3.633

4.  Bone disease in primary hyperparathyrodism.

Authors:  Claudio Marcocci; Luisella Cianferotti; Filomena Cetani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

5.  Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.

Authors:  Marcella D Walker; Elaine Cong; James A Lee; Anna Kepley; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

6.  Effect of gender and geographic location on the expression of primary hyperparathyroidism.

Authors:  F De Lucia; S Minisola; E Romagnoli; J Pepe; C Cipriani; A Scillitani; N Parikh; D S Rao
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

7.  Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism.

Authors:  Marcella D Walker; Elaine Cong; Anna Kepley; Marco R Di Tullio; Tatjana Rundek; Shunichi Homma; James A Lee; Rui Liu; Polly Young; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

8.  Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications.

Authors:  G Guardia; N Parikh; T Eskridge; E Phillips; G Divine; D Sudhaker Rao
Journal:  Osteoporos Int       Date:  2007-09-18       Impact factor: 4.507

9.  Effect of concomitant vitamin D deficiency or insufficiency on lumbar spine volumetric bone mineral density and trabecular bone score in primary hyperparathyroidism.

Authors:  M D Walker; I Saeed; J A Lee; C Zhang; D Hans; T Lang; S J Silverberg
Journal:  Osteoporos Int       Date:  2016-05-19       Impact factor: 4.507

10.  Management of hypovitaminosis D in patients with primary hyperparathyroidism.

Authors:  M S Rathi; S Gonzalez; D Wright; N R Ellis; S R Peacey
Journal:  J Endocrinol Invest       Date:  2014-02-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.